OverviewSuggest Edit

Amarin is a clinical-stage biopharmaceutical company with a focus on cardiovascular disease. The Company’s lead product candidate is AMR101, a prescription grade Omega-3 product comprising not less than 96% ultra-pure ethyl eicosapentaenoic acid (EPA), which is entering Phase 3 clinical trials for the treatment of hypertriglyceridemia and mixed dyslipidemia. Amarin also has next-generation lipid candidates under evaluation for preclinical development. Amarin recently established its research and development headquarters in Mystic, Connecticut with an experienced research and development team. Amarin’s programs capitalize on its lipid science expertise and the known therapeutic benefits of Omega-3 products in treating cardiovascular disease. Amarin has a number of non-core programs for partnering in the area of central nervous system (CNS) disorders, including Huntington’s disease, myasthenia gravis and Parkinson’s disease.
TypePublic
Founded1991
HQDublin, IE
Websiteamarincorp.com
Employee Ratings4.1

Latest Updates

Employees (est.) (May 2021)1,000(+4%)
Job Openings40
Revenue (FY, 2020)$614.1 M(+43%)
Share Price (May 2021)$5(-2%)
Cybersecurity ratingCMore

Key People/Management at Amarin

Colin Stewart

Colin Stewart

President and CEO
Joseph S. Zakrzewski

Joseph S. Zakrzewski

Executive Chairman and Chief Executive Officer
John Thero

John Thero

CFO
Declan Doogan

Declan Doogan

Chief Medical Officer
Show more

Amarin Office Locations

Amarin has offices in Dublin and Bridgewater Township
Dublin, IE (HQ)
Block C, 77 Sir John Rogerson's Quay, Dublin Docklands
Dublin, IE
Pembroke House Pembroke Street Upper
Bridgewater Township, NJ, US
440 US-22
Show all (3)

Amarin Financials and Metrics

Amarin Revenue

Amarin's revenue was reported to be $614.06 m in FY, 2020
USD

Revenue (Q1, 2021)

142.2m

Gross profit (Q1, 2021)

113.8m

Gross profit margin (Q1, 2021), %

80.1%

Net income (Q1, 2021)

(1.6m)

EBIT (Q1, 2021)

(1.3m)

Market capitalization (3-May-2021)

2.0b

Closing stock price (3-May-2021)

5.0

Cash (31-Mar-2021)

291.0m

EV

1.7b
Amarin's current market capitalization is $2 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

26.4m54.2m81.8m130.1m181.1m229.2m429.8m614.1m

Revenue growth, %

106%51%59%39%27%

Cost of goods sold

11.9m20.5m27.9m34.4m45.0m54.5m96.0m131.4m

Gross profit

14.4m33.7m53.9m95.7m136.2m174.7m333.7m482.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

5.5m15.9m17.7m21.5m25.5m33.1m32.7m34.6m45.2m47.4m43.9m52.6m55.3m73.3m100.8m112.4m155.0m135.3m156.5m142.2m

Cost of goods sold

2.8m3.7m4.2m5.0m5.4m5.6m6.4m7.5m6.9m8.9m8.5m8.2m11.4m11.9m10.6m12.8m13.5m17.1m22.8m25.4m34.8m28.8m33.1m28.3m

Gross profit

2.7m10.3m11.3m14.0m18.6m24.3m24.3m26.4m33.8m35.4m33.3m39.8m41.8m56.1m78.0m87.0m120.2m106.5m123.4m113.8m

Gross profit Margin, %

48%65%64%65%73%73%74%76%75%75%76%76%76%77%77%77%78%79%79%80%
USDQ2, 2011

Financial Leverage

-0.9 x
Show all financial metrics

Amarin Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

SecurityScorecard logo

Amarin Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Amarin Online and Social Media Presence

Embed Graph

Amarin News and Updates

Amarin Reports First Quarter 2021 Financial Results and Provides Business Update

Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19 Recedes

Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel

DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that Joseph T. Kennedy has informed the board of directors of his decision to retire as executive vice president, general counsel and strategic initiatives. A search is u…

Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2

VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication1,2,3

Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021

DUBLIN, Ireland and BRIDGEWATER, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2021 financial results and provide an operational updat…

Amarin Announces CEO Succession Plan

John Thero to Retire as President and CEO on August 1, 2021
Show more

Amarin Blogs

VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021

28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association’s Virtual

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting (CABG) Procedures in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Heart Association’s Virtual Content Import Fri, 11/13/2020 - 10:00 …

Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention - insights from REDUCE-IT PCI.

Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention - insights from REDUCE-IT PCI. jennifer.segal… Thu, 11/12/2020 - 18:26 Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary i…

REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups.

REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups. jennifer.segal… Thu, 11/12/2020 - 18:16 REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups. M…

Eicosapentaenoic acid (EPA) inhibits human low-density lipoprotein oxidation in a concentration- and time-dependent manner at pharmacologic doses in vitro [abstract EAS19-0568].

Eicosapentaenoic acid (EPA) inhibits human low-density lipoprotein oxidation in a concentration- and time-dependent manner at pharmacologic doses in vitro [abstract EAS19-0568]. jennifer.segal… Thu, 11/12/2020 - 18:00 Eicosapentaenoic acid (EPA) inhibits human low-density lipoprotein oxid…

Eicosapentaenoic acid, but not a mixed omega-3 fatty acid supplement, improved nitric oxide bioavailability in human endothelial cells in vitro.

Eicosapentaenoic acid, but not a mixed omega-3 fatty acid supplement, improved nitric oxide bioavailability in human endothelial cells in vitro. jennifer.segal… Thu, 11/12/2020 - 17:57 Eicosapentaenoic acid, but not a mixed omega-3 fatty acid supplement, improved nitric oxide bioavailabil…
Show more

Amarin Frequently Asked Questions

  • When was Amarin founded?

    Amarin was founded in 1991.

  • Who are Amarin key executives?

    Amarin's key executives are Colin Stewart, Joseph S. Zakrzewski and John Thero.

  • How many employees does Amarin have?

    Amarin has 1,000 employees.

  • What is Amarin revenue?

    Latest Amarin annual revenue is $614.1 m.

  • What is Amarin revenue per employee?

    Latest Amarin revenue per employee is $614.1 k.

  • Who are Amarin competitors?

    Competitors of Amarin include Recro Gainesville, Amicus Therapeutics and Circassia.

  • Where is Amarin headquarters?

    Amarin headquarters is located at Block C, 77 Sir John Rogerson's Quay, Dublin Docklands, Dublin.

  • Where are Amarin offices?

    Amarin has offices in Dublin and Bridgewater Township.

  • How many offices does Amarin have?

    Amarin has 3 offices.